Calidi Biotherapeutics Inc

Calidi Biotherapeutics reveals potent pre‑clinical data for CLD‑401, its IL‑15‑armed oncolytic virus, showing strong TME immune activation and a safe profile ahead of a 2026 IND filing.

Calidi Biotherapeutics unveils its RedTail virotherapy platform, a targeted gene‑therapy breakthrough for solid tumors, advancing IL‑15 and T‑cell engagers toward clinical trials.

Calidi Biotherapeutics: a San Diego‑based clinical‑stage immuno‑oncology firm developing targeted therapies to attack solid tumors and empower the immune system, driving future cancer treatment growth.

Calidi Biotherapeutics, a clinical-stage immuno-oncology company, faces a critical crossroads as it navigates the challenges of bringing its innovative cancer treatments to market.

Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company with a promising mission to revolutionize cancer treatment, but its financial volatility and lack of profitability raise questions about its long-term viability.

Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company pioneering a new approach to cancer treatment by harnessing the body’s immune system to target and destroy cancer cells.

Calidi Biotherapeutics Inc. is pioneering a new era in cancer treatment with its precision genetic medicine platform, aiming to revolutionize the treatment of metastatic cancer and other conditions with unmet medical needs.